Table 1.

Patients receiving oritavancin to treat culture-positive osteomyelitis—results per pathogen, methicillin-resistant Staphylococcus aureus

Reference	Sex/age (years)	Site of infection	Antimicrobials prior to oritavancin	Oritavancin dosing regimen	Concomitant antimicrobials	Outcome	Time of follow-up	Adverse events
Chastain et al. [44]	M/65	Right great toe	None	1200 mg × 2; on days 1 and 13	Doxycycline × 3 months	Clinical cure	6 months	None reported
	M/31	Left distal metatarsal	Clindamycin × 1 week	1200 mg × 3 on days 1, 52, and 90	None	Clinical cure	6 months	None reported
	M/47	Right distal first metatarsal	Clindamycin × 1 week, then doxycycline × 3 months	1200 mg × 2; on days 1 and 72	None	Clinical cure	6 months	None reported
	F/89	Left lateral malleolus	None	1200 mg × 4; on days 1, 36, 73, and 147	None	Clinical cure	6 months	None reported
	M/62	Right calcaneus	None	1200 mg × 6; on days 1, 14, 28, 70, 84, and 113	None	Clinical cure	6 months	None reported
Ruggero et al. [41]	M/46	Native, vertebral osteomyelitis	Aztreonam, vancomycin, metronidazole, doxycycline, TMP/SMX	1200 mg every 2 weeks × 4 doses, then 1200 mg 1 month later	TMP/SMX	Clinical improvement	5 months, and 1 year	None reported
CHROME Registry [46]	F/47	Not specified	TMP/SMX	1200 mg × 1	None	Failure	N/A	None reported
	F/70	Not specified	None	1200 mg × 10 doses every 7–8 days	None	Clinical improvement	N/A	None reported
	F/46	Skull	Vancomycin	1200 mg × 6 doses every 7–14 days	None	Clinical cure	N/A	None reported
	M/58	Left foot	Minocycline, vancomycin	1200 mg × 1, then in 14 days, AE occurred with second dose	Linezolid	Clinical improvement	N/A	Infusion discontinued; moderate, not serious infusion-related reaction; sent to ED for observation
	F/47	Not specified	None	1200 mg × 2 doses every 9 days	TMP/SMX	Failure	N/A	None reported

M male, F female, TMP/SMX trimethoprim/sulfamethoxazole, AE adverse event, ED emergency department, N/A information not available